John Hovanesian, MD
Harvard Eye Associates
6
6
4
N/A
0
14
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+1 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
William Trattler, MD
The Center for Excellence in Eye Care
Shared therapeutic areas:
Worked with same sponsors:
Gregg Berdy, MD
Ophthalomology Associates
Shared therapeutic areas:
Worked with same sponsors:
Jonathan Davidorf, MD
Davidorf Eye Group
Shared therapeutic areas:
Worked with same sponsors:
Jodi Luchs, MD
South Shore Eye Care LLP
Shared therapeutic areas:
Worked with same sponsors:
Jonathan Talamo, MD
Talamo Laser Eye Center
Shared therapeutic areas:
Worked with same sponsors:
Parag Majmudar, MD
Chicago Cornea Consultants, LTD
Shared therapeutic areas:
Worked with same sponsors:
Audrey Rostov, MD
Northwest Eye Surgeons
Shared therapeutic areas:
Worked with same sponsors:
Lance Forstot
Corneal Consultants of Colorado, P.C
Shared therapeutic areas:
Worked with same sponsors:
Sandy Feldman, MD
Clear View Eye & Laser Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Shamik Bafna, MD
Cleveland Eye Clinic
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
2311 TURGOR Study -Surgical Efficiency and Postoperative Corneal Clarity With Near Physiologic vs High IOP Settings
The THINK Study Incidence of Neurotrophic Keratopathy)
Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification
All 6 trials loaded